Lipodystrophy clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Daily Subcutaneous Metreleptin Treatment in Subjects With PL
open to eligible people ages 12 years and up
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
at UC Davis
Last updated: